CN104394934B - 包含至少一种透明质酸及至少一种蔗糖八硫酸酯水溶性盐的在水性介质中的组合物 - Google Patents

包含至少一种透明质酸及至少一种蔗糖八硫酸酯水溶性盐的在水性介质中的组合物 Download PDF

Info

Publication number
CN104394934B
CN104394934B CN201380031227.6A CN201380031227A CN104394934B CN 104394934 B CN104394934 B CN 104394934B CN 201380031227 A CN201380031227 A CN 201380031227A CN 104394934 B CN104394934 B CN 104394934B
Authority
CN
China
Prior art keywords
composition
hyaluronic acid
composition according
sucrose octasulfate
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380031227.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN104394934A (zh
Inventor
埃斯特尔·皮龙
热雷米·邦贝唐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Vivacy SAS
Original Assignee
Laboratoires Vivacy SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Vivacy SAS filed Critical Laboratoires Vivacy SAS
Publication of CN104394934A publication Critical patent/CN104394934A/zh
Application granted granted Critical
Publication of CN104394934B publication Critical patent/CN104394934B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201380031227.6A 2012-06-13 2013-06-13 包含至少一种透明质酸及至少一种蔗糖八硫酸酯水溶性盐的在水性介质中的组合物 Active CN104394934B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261659140P 2012-06-13 2012-06-13
US61/659,140 2012-06-13
FR1255543 2012-06-13
FR1255543A FR2991876B1 (fr) 2012-06-13 2012-06-13 Composition, en milieu aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate
PCT/FR2013/051380 WO2013186493A2 (fr) 2012-06-13 2013-06-13 Composition, en milieux aqueux, comprenant au moins un acide hyaluronique et au moins un sel hydrosoluble de sucrose octasulfate

Publications (2)

Publication Number Publication Date
CN104394934A CN104394934A (zh) 2015-03-04
CN104394934B true CN104394934B (zh) 2018-01-09

Family

ID=46785648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380031227.6A Active CN104394934B (zh) 2012-06-13 2013-06-13 包含至少一种透明质酸及至少一种蔗糖八硫酸酯水溶性盐的在水性介质中的组合物

Country Status (17)

Country Link
US (1) US9314530B2 (enExample)
EP (1) EP2861301B1 (enExample)
JP (1) JP6178414B2 (enExample)
KR (1) KR20150023468A (enExample)
CN (1) CN104394934B (enExample)
AU (1) AU2013276343B2 (enExample)
BR (1) BR112014029510A2 (enExample)
CA (1) CA2876057A1 (enExample)
EA (1) EA201492208A1 (enExample)
ES (1) ES2728686T3 (enExample)
FR (1) FR2991876B1 (enExample)
IL (1) IL235776A0 (enExample)
MX (1) MX354544B (enExample)
PL (1) PL2861301T3 (enExample)
SG (1) SG11201407857SA (enExample)
TR (1) TR201907427T4 (enExample)
WO (1) WO2013186493A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492474B2 (en) 2013-07-10 2016-11-15 Matrix Biology Institute Compositions of hyaluronan with high elasticity and uses thereof
US9421198B2 (en) 2013-07-30 2016-08-23 Teoxane Composition comprising hyaluronic acid and mepivacaine
FR3015290B1 (fr) * 2013-12-23 2017-01-13 Lab Vivacy Compositions d'acide hyaluronique compreant de la mepivacaine
ES2898656T3 (es) * 2014-06-30 2022-03-08 Nutricos Tech Productos de combinación y composiciones cosméticas para luchar contra los trastornos de la piel y su envejecimiento que afectan a los queratinocitos y/o los fibroblastos y la dermis
FR3032617B1 (fr) * 2015-02-16 2018-03-16 Kylane Laboratoires Sa Procede de preparation d un hydrogel injectable; hydrogel obtenu; utilisation de l hydrogel obtenu
FR3036035B1 (fr) 2015-05-11 2018-10-05 Laboratoires Vivacy Compositions comprenant au moins un polyol et au moins un anesthesique
US10004824B2 (en) 2015-05-11 2018-06-26 Laboratoires Vivacy Compositions comprising at least one polyol and at least one anesthetic
CN104926889A (zh) * 2015-05-24 2015-09-23 广西师范学院 蔗糖硫酸酯铜银类化合物及其制作方法和用途
PT3842047T (pt) * 2015-09-24 2024-09-19 Matrix Biology Inst Composições de hialuronano de elevada elasticidade e processos para o seu uso
FR3044557B1 (fr) * 2015-12-07 2017-12-01 Benedicte Vincente Gavard Molliard Tauzin Nouvelle composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
WO2017102001A1 (fr) 2015-12-16 2017-06-22 Vplus International Sa Composition d'acide hyaluronique pour injections peniennes
FR3047666A1 (fr) * 2016-02-15 2017-08-18 Benedicte Vincente Gavard Molliard Tauzin Composition injectable; procede de preparation de ladite composition; utilisation de ladite composition
FR3058064B1 (fr) 2016-10-28 2020-08-07 Lab Vivacy Composition a base d'acide hyaluronique comprenant de la mepivacaine
WO2018107226A1 (en) * 2016-12-13 2018-06-21 Beta Therapeutics Pty. Ltd. Methods of treating ocular disorders
BR112019012045A2 (pt) 2016-12-13 2020-08-18 Beta Therapeutics Pty Ltd inibidores de heparanase e uso dos mesmos
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
FR3109153B1 (fr) 2020-04-10 2022-07-15 Teoxane SA Compositions à base d’au moins deux glycosaminoglycanes
KR102664134B1 (ko) * 2023-11-23 2024-05-10 한국콜마주식회사 히알루론산 및 이의 유도체를 포함하는 화장료 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0640346A1 (en) * 1987-12-21 1995-03-01 BM Research A/S Uses of sulphated sugars against inflammation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2715091A (en) 1949-11-28 1955-08-09 Nat Res Dev Dextran sulfate as anticoagulant, process of preparing same, and sterile solution thereof
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US5916880A (en) 1987-12-21 1999-06-29 Bukh Meditec A/S Reduction of skin wrinkling using sulphated sugars
DK86492D0 (da) 1992-06-30 1992-06-30 Bukh Meditec Laegemiddel
WO1998022114A1 (en) 1996-11-15 1998-05-28 Dumex-Alpharma A/S A method for promoting tissue repair
JP2000178196A (ja) * 1998-12-11 2000-06-27 Seikagaku Kogyo Co Ltd 新規ヒアルロニダーゼ阻害剤及び外用剤
GB9902412D0 (en) 1999-02-03 1999-03-24 Fermentech Med Ltd Process
EP1423081A4 (en) * 2001-06-25 2005-05-25 Depuy Int Ltd COMPOSITION WITH GLYCOSAMINOGYCANES AND HYALURONIDASE INHIBITORS FOR THE TREATMENT OF ARTHRITIC JOINTS
US20050187150A1 (en) * 2001-10-31 2005-08-25 New York University Structure-based design and synthesis of FGF inhibitors and FGF modulator compounds
MXPA01011542A (es) 2001-11-13 2003-05-22 Alcon Inc Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel.
AUPS052802A0 (en) 2002-02-15 2002-03-07 Praxis Pharmaceuticals International Pty Ltd Carbohydrate-based anti-wrinkle and tissue remodelling compounds
US20080003258A1 (en) 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
AU2003295347B2 (en) 2002-10-16 2010-02-11 Arthrodynamic Holdings, Llc Treatment for traumatic synovitis and damaged articular cartilage
FR2861734B1 (fr) 2003-04-10 2006-04-14 Corneal Ind Reticulation de polysaccharides de faible et forte masse moleculaire; preparation d'hydrogels monophasiques injectables; polysaccharides et hydrogels obtenus
GB0329907D0 (en) 2003-12-23 2004-01-28 Innomed Ltd Compositions
FR2865737B1 (fr) 2004-02-03 2006-03-31 Anteis Sa Gel reticule biocompatible
US20090215717A1 (en) 2004-08-05 2009-08-27 Ivax Drug Research Institute Ltd. Sulfated oligosaccharides
AU2005272578A1 (en) * 2004-08-13 2006-02-23 Angiotech International Ag Compositions and methods using hyaluronic acid and hyluronidase inhibitors
MX2009000885A (es) 2006-07-25 2009-02-05 Osmotica Corp Soluciones oftalmicas.
JPWO2008020495A1 (ja) * 2006-08-15 2010-01-07 東京化成工業株式会社 新規阻害剤
FR2918276B1 (fr) 2007-07-02 2010-01-22 Anteis Sa "utilisation d'un gel de polysaccharide(s)naturel(s)pour la preparation d'une formulation injectable de traitement des degenerescences articulaires"
ITMI20072237A1 (it) 2007-11-27 2009-05-28 Sigea Srl Esteri misti butirrico-formico di polisaccaridi acidi, loro preparazione ed uso come dermocosmetici
US8394784B2 (en) * 2007-11-30 2013-03-12 Allergan, Inc. Polysaccharide gel formulation having multi-stage bioactive agent delivery
FR2924615B1 (fr) 2007-12-07 2010-01-22 Vivacy Lab Hydrogel cohesif biodegradable.
FR2953522B1 (fr) 2009-12-07 2012-03-09 Fabre Pierre Dermo Cosmetique Sucrose octasulfates de zinc, leur preparation et leurs applications pharmaceutiques et cosmetiques
US20110171310A1 (en) 2010-01-13 2011-07-14 Allergan Industrie, Sas Hydrogel compositions comprising vasoconstricting and anti-hemorrhagic agents for dermatological use
FR2956322A1 (fr) 2010-02-17 2011-08-19 Urgo Lab Utilisation d'oligosaccharides polysulfates synthetiques comme agents de detersion d'une plaie.
CA2805008C (en) * 2010-07-12 2015-05-12 Shin Poong Pharmaceutical Co., Ltd. Filler composition for tissue augmentation comprising a hydrogel of hyaluronic acid cross-linked with alkylene diamine
FR2983483B1 (fr) 2011-12-02 2014-11-14 Vivacy Lab Procede de substitution et reticulation simultanees d'un polysaccharide via ses fonctions hydroxyles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0640346A1 (en) * 1987-12-21 1995-03-01 BM Research A/S Uses of sulphated sugars against inflammation

Also Published As

Publication number Publication date
CN104394934A (zh) 2015-03-04
JP2015525099A (ja) 2015-09-03
AU2013276343B2 (en) 2017-06-15
AU2013276343A1 (en) 2014-12-04
IL235776A0 (en) 2015-01-29
KR20150023468A (ko) 2015-03-05
EP2861301B1 (fr) 2019-02-20
PL2861301T3 (pl) 2020-08-24
FR2991876B1 (fr) 2014-11-21
TR201907427T4 (tr) 2019-06-21
EA201492208A1 (ru) 2015-04-30
MX2014013949A (es) 2015-05-11
BR112014029510A2 (pt) 2017-06-27
MX354544B (es) 2018-03-09
SG11201407857SA (en) 2015-02-27
WO2013186493A3 (fr) 2014-05-08
US9314530B2 (en) 2016-04-19
JP6178414B2 (ja) 2017-08-09
ES2728686T3 (es) 2019-10-28
CA2876057A1 (fr) 2013-12-19
EP2861301A2 (fr) 2015-04-22
FR2991876A1 (fr) 2013-12-20
US20140005140A1 (en) 2014-01-02
WO2013186493A2 (fr) 2013-12-19

Similar Documents

Publication Publication Date Title
CN104394934B (zh) 包含至少一种透明质酸及至少一种蔗糖八硫酸酯水溶性盐的在水性介质中的组合物
US10058499B2 (en) Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate
CN103702659B (zh) 包括抗氧化剂的皮肤填充剂组合物
CN103415307B (zh) 透明质酸组合物
EP3381438B2 (en) Composition for injection of hyaluronic acid, containing hyaluronic acid derivative and dna fraction, and use thereof
EP3047844B1 (en) Polysaccharide gel formulation
KR101459070B1 (ko) 지속성을 갖는 히알루론산 겔 조성물
EP3324931B1 (en) In situ cross-linkable polysaccharide compositions and uses thereof
CN105916512B (zh) 包含甲哌卡因的透明质酸组合物
AU2018260925B2 (en) Polysaccharide gel formulation
JP2024524990A (ja) 局所麻酔薬を含む架橋ヒアルロン酸組成物
KR20160102723A (ko) 소듐 2-메르캅토에탄 설포네이트를 삼투압 조절제로서 함유하는 생체투여 또는 미용성형용 생분해성 고분자 조성물
HK1238179B (zh) 包含至少一种透明质酸和抗坏血酸磷酸酯镁的经灭菌组合物
HK1238179A1 (en) Sterilized composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate
HK1208350B (en) Sterilised composition comprising at least one hyaluronic acid and magnesium ascorbyl phosphate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder

Address after: France

Patentee after: Vivacy Lab

Address before: Alger, France

Patentee before: Vivacy Lab

CP02 Change in the address of a patent holder